S. Martsevich, Yulia V. Lukina, O. Lerman, N. Kutishenko, A. R. Kiselev, O. Drapkina
{"title":"Self-awareness Regarding Obesity and Specific Therapy in Patients with\nOverweight or Obesity and Cardiovascular Diseases from Moscow Region","authors":"S. Martsevich, Yulia V. Lukina, O. Lerman, N. Kutishenko, A. R. Kiselev, O. Drapkina","doi":"10.2174/0115748855261762231011050708","DOIUrl":null,"url":null,"abstract":"\n\nDespite the proven effectiveness of lifestyle interventions and specific medications\nin the treatment of obesity, little is known about their use in real-world practice. Aim – to\nstudy the awareness of patients about the problem of overweight/obesity, as well as the clinical\npractice of non-drug and drug therapy according to the survey.\n\n\n\nEligible patients were recruited from the prospective outpatient registry of\npatients with cardiovascular diseases. The design of the study was a cross-sectional cohort singlecentre.\nAll of the included patients completed a specifically designed questionnaire. The study included\n295 patients (mean age 66.8 ± 11.8 years) with a body mass index (BMI) of ≥25 kg/m2. One\nhundred eight (36.6%) individuals were overweight, 124 (42.2%) had first-class obesity, 42 (14.2%)\nhad second-class obesity, and 21 (7.1%) patients had third-class obesity.\n\n\n\n252 patients (85.4%) were informed of being overweight/obese, and all of them received\nnon-drug recommendations for the treatment of obesity. Anti-obesity medications (AOM) were\nrecommended only to 25 (8.5%) patients: 3 – overweight, 11 – obesity class I, 6 obesity class II,\nand 5 – obesity class III. Twenty-one (7.1%) patients took the prescribed medications (84% adherence).\nThe drugs were more often taken by patients with class II and III disease (40.5% and 57.1%\nof patients, respectively). Overweight (8.5%) and class I obesity (18.0%) patients took these drugs\nless often (p<0.0001).\n\n\n\nThe results of the survey have demonstrated good awareness of patients about their\nobesity/overweight and quite frequent use of non-drug obesity therapy. However, the rate of AOM\nprescription was extremely low.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748855261762231011050708","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Despite the proven effectiveness of lifestyle interventions and specific medications
in the treatment of obesity, little is known about their use in real-world practice. Aim – to
study the awareness of patients about the problem of overweight/obesity, as well as the clinical
practice of non-drug and drug therapy according to the survey.
Eligible patients were recruited from the prospective outpatient registry of
patients with cardiovascular diseases. The design of the study was a cross-sectional cohort singlecentre.
All of the included patients completed a specifically designed questionnaire. The study included
295 patients (mean age 66.8 ± 11.8 years) with a body mass index (BMI) of ≥25 kg/m2. One
hundred eight (36.6%) individuals were overweight, 124 (42.2%) had first-class obesity, 42 (14.2%)
had second-class obesity, and 21 (7.1%) patients had third-class obesity.
252 patients (85.4%) were informed of being overweight/obese, and all of them received
non-drug recommendations for the treatment of obesity. Anti-obesity medications (AOM) were
recommended only to 25 (8.5%) patients: 3 – overweight, 11 – obesity class I, 6 obesity class II,
and 5 – obesity class III. Twenty-one (7.1%) patients took the prescribed medications (84% adherence).
The drugs were more often taken by patients with class II and III disease (40.5% and 57.1%
of patients, respectively). Overweight (8.5%) and class I obesity (18.0%) patients took these drugs
less often (p<0.0001).
The results of the survey have demonstrated good awareness of patients about their
obesity/overweight and quite frequent use of non-drug obesity therapy. However, the rate of AOM
prescription was extremely low.
期刊介绍:
Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.